CMS In Brief

Latest news from the Medicare agency includes updates from the physician fee schedule and clinical laboratory fee schedule, an American Hospital Association lawsuit, and more.

In a CMS-commissioned report released Nov. 7, the HHS Office of Inspector General found that suppliers’ improper billing of beneficiaries for non-mail order diabetes test strips contributed to a 33% increase in non-mail order test strip claims in competitive bidding areas from 2010-2011. During the same time period, less expensive mail order supplies were found to have decreased by 71%. OIG discovered that for 20% of the 211 beneficiaries reviewed for the report, suppliers had improperly billed Medicare for the non-mail order diabetes test strips in 2011, whereas beneficiaries reported having received the less expensive mail order test strips. In addition, 23% of beneficiaries reviewed by OIG reported supplier activities – such as waiving their co-payments and sending them unsolicited testing supplies – that OIG determined to be inappropriate. While OIG made no recommendations in the report, it noted that this information could be useful to CMS as the agency prepares to implement the national mail order competition for diabetes suppliers as part of it its durable medical equipment, prosthetics/orthotics and supplies competitive bidding program, projected to begin in 2013.

CMS released estimated payment rates for three new Category 1 CPT codes – totaling $833 in aggregate – related to procedures using Abiomed Inc.’s Impella heart pump, the company...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

Guardant’s Multi-Cancer Detection Test Granted FDA Breakthrough Device Designation

 

Guardant Health’s methylation-based blood test – Shield MCD – showed a specificity of 98.6% and sensitivity of 75% across eight cancer types in its clinical validation data presented at ASCO.

‘Dawn Of FDA’s AI Era’ Has Arrived. Makary Announces Early Implentation Of ‘Elsa’ Platform

 

US FDA Commissioner Marty Makary says the agency’s generative AI tool ‘Elsa’ will allow employees across the FDA to work more efficiently. The commissioner says Elsa’s launch comes ahead of schedule following a successful pilot program.

Medtech Experts Debate EU Recertification Gridlock

 

Modifying or doing away with the EU medtech recertification requirement is far from straightforward. Four experts from an EU national authority, an EU notified body trade association and industry, plus a well-known medtech consultant, reflect on how to move forward.

DeepLook AI Imaging Provides A Deeper Look At Dense Breast

 

DeepLook Medical recently announced the commercial rollout of DL Precise, an AI-powered imaging platform that enhances breast cancer screening, at major healthcare institutions across the US.

More from Medtech Insight

GE HealthCare Announces US Launch Of Longer Half-Life PET MPI Agent For Ischemia Detection

 
• By 

GE HealthCare is pursuing a dual-front imaging strategy with its PET MIP agent Flyrcado for detecting artery disease: It lasts longer than current PET scan tracers and allows patients to do treadmill-based stress tests alongside the scan.

DeepLook AI Imaging Provides A Deeper Look At Dense Breast

 

DeepLook Medical recently announced the commercial rollout of DL Precise, an AI-powered imaging platform that enhances breast cancer screening, at major healthcare institutions across the US.

First AI Breast Cancer Prediction Platform Receives FDA Authorization

 

Clairity’s "first-in-class" mammography-based AI screening tool, Clairity Breast, provides "equitable risk assessments," expanding access to lifesaving early detection for breast cancer, said company founder Connie Lehman.